Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red tra...
3600 Holly Lane North
Plymouth, MN 55447
Founded in 2006
Entellus Medical, Inc. Announces Collaboration with Fiagon NA Corporation
Aug 10 15
Entellus Medical, Inc. announced a collaboration with Fiagon NA Corporation. The agreement enables Entellus to be the exclusive distributor of Fiagon Image Guidance Systems ("IGS") for ENT offices and ENT Ambulatory Surgery Centers in the United States. The company expects the integration of the Entellus XprESS Pro Multi-Sinus Dilation System and the Fiagon IGS to provide another level of confirmation to increase physician confidence in device placement. Entellus Medical's systems deliver proven results that are equivalent to those obtained through traditional sinus surgery, while at the same time providing an improved patient experience. The addition of the Fiagon IGS in the office setting has the potential to continue the expansion of ENT surgical procedures into the office setting through positive clinical outcomes and reduced costs to both the patient and healthcare system.
Entellus Medical, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of 2015
Aug 6 15
Entellus Medical, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $15,191,000 against $12,498,000 a year ago. Loss from operations was $2,354,000 against $651,000 a year ago. Net loss was $2,868,000 or $0.15 per basic and diluted share against $1,173,000 or $0.81 per basic and diluted share a year ago.
For six months, revenue was $28,693,000 against $22,673,000 a year ago. Loss from operations was $5,804,000 against $2,770,000 a year ago. Net loss was $7,216,000 or $0.46 per basic and diluted share against $3,708,000 or $2.59 per basic and diluted share a year ago.
The company estimates that third quarter 2015 revenue will range from approximately $13.9 million to $14.4 million, which would represent growth of approximately 19% to 23% versus the third quarter of 2014. The company expects that gross margin for the third quarter of 2015 will range from 77.5% to 78.5% compared to 78.6% in the third quarter of 2014. Third quarter net loss is estimated to range from approximately $3.7 million to $5.3 million, or an estimated net loss of $0.20 to $0.28 per share. The estimated net loss for the third quarter includes estimated non-cash stock-based compensation of $0.7 million to $0.8 million.
The company continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million, representing growth of 20% to 25% annually, and that gross margin will be in a range of 77% to 78% for 2015. Full year 2015 net loss is expected to be in a range of $14.0 million to $19.0 million, or a net loss of $0.80 to $1.10 per share.
Entellus Medical, Inc. to Report Q2, 2015 Results on Aug 06, 2015
Jul 23 15
Entellus Medical, Inc. announced that they will report Q2, 2015 results After-Market on Aug 06, 2015